Skip to page content

Stealth biotech startup Accipiter raises $7.9 million, filing shows


test tube
Accipiter Biosciences disclosed the raise in a Friday filing with the Securities and Exchange Commission.
luchschen

Seattle-based biotech Accipiter Biosciences has raised $7.9 million, according to a Friday filing with the Securities and Exchange Commission.

The funding was an equity raise, according to the filing, and Accipiter is looking to raise an additional $5.8 million. The filing lists Matthew Bick as CEO of the startup. Bick's LinkedIn page simply notes he is the CEO and co-founder of a stealth-mode biotech.

Bick didn't respond to a message seeking for more information.

Accipiter doesn't list a website on LinkedIn, and internet searches don't readily reveal a website. In the SEC filing, Accipiter lists 1616 Eastlake Ave. E. as its headquarters.


Related coverage

Pack Ventures, a venture capital fund that launched in 2022, says on its website it has backed Accipiter. Pack Ventures' website says the company is "developing the next-generation of multifunctional biologics using state-of-the-art computational methods."

Pack Ventures supports students, faculty and alumni connected to the University of Washington, and the fund is open to those both on and off campus. Bick's LinkedIn page notes he was a senior fellow at UW for more than seven years.

The SEC filing lists Heather Gorham as a director at Accipiter. Gorham is a principal at Seattle-based venture capital firm Flying Fish Partners. Gorham joined Flying Fish in February of last year, before which she spent more than four years at J.P. Morgan, the commercial and investment banking arm of JPMorgan Chase & Co.

In an email to the Business Journal, Gorham said the firm had no comment on the fundraise at this time.

Before launching his stealth-mode biotech, Bick spent more than two years at Seattle-based biotech Neoleukin Therapeutics, his LinkedIn page shows. Neoleukin's lead candidate was a protein therapeutic aimed at cancer immunotherapy, but the company discontinued that candidate and laid off 40% of its staff in November 2022. The company laid off about 70% of its staff in March 2023. It was absorbed by New York City-based biotech Neurogene in December through a reverse merger.


For more stories like this one, sign up for Seattle Inno newsletters from the Puget Sound Business Journal and the American Inno network.


Keep Digging



SpotlightMore

Nancy Xiao (left) and Jim Xiao (right) are swapping roles at Seattle-based Mason.
See More
SPOTLIGHT Awards
See More
Image via Getty
See More
Image via Getty Images
See More

Upcoming Events More

Oct
03
TBJ
Oct
17
TBJ

Want to stay ahead of who & what is next? Sent weekly, the Beat is your definitive look at Seattle’s innovation economy, offering news, analysis & more on the people, companies & ideas driving your region forward. Follow the Beat.

Sign Up